Alivus Life Sciences (NSE:ALIVUS) Beginning Cash Position: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ALIVUS Alivus Life Sciences Ltd NSE:ALIVUS
80 GF Score
Price ₹1,329.80
GF Value ₹1,026.06
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Alivus Life Sciences Beginning Cash Position?

Alivus Life Sciences NSE:ALIVUS +0.35% 80 Beginning Cash Position is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:ALIVUS with a GF Score™ of 80/100 and a GF Value™ of ₹1,026.06 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Alivus Life Sciences's Beginning Cash Position for the quarter that ended in Jun. 2026 was ₹0 Mil.

Alivus Life Sciences's annual Beginning Cash Position increased from Mar. 2024 (₹2,838 Mil) to Mar. 2025 (₹3,014 Mil) but then declined from Mar. 2025 (₹3,014 Mil) to Mar. 2026 (₹711 Mil).

Alivus Life Sciences Beginning Cash Position Related Terms

Alivus Life Sciences Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Alivus Life Sciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alivus Life Sciences Beginning Cash Position Chart

Alivus Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beginning Cash Position
Get a 7-Day Free Trial 1,155.96 5,121.57 2,838.23 3,014.14 710.62

Alivus Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:ALIVUS
80GF Score
Alivus Life Sciences Ltd NSE:ALIVUS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alivus Life Sciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of ₹0 Mil mean?
Alivus Life Sciences (NSE:ALIVUS) has a Beginning Cash Position of ₹0 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Alivus Life Sciences and its competitors.
Is Alivus Life Sciences' Beginning Cash Position too high?
Alivus Life Sciences' current Beginning Cash Position is ₹0 Mil. Overall, Alivus Life Sciences has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Beginning Cash Position compare to ZTS?
Alivus Life Sciences' Beginning Cash Position of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Alivus Life Sciences and its competitors. Alivus Life Sciences's current Beginning Cash Position is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,026.06, compared to a current price of ₹1,329.80 — trading 29.6% above its estimated fair value. The current Beginning Cash Position is ₹0 Mil. Alivus Life Sciences' overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Beginning Cash Position is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?

Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued. The current stock price of ₹1,329.80 is trading 29.6% above its estimated GF Value™ of ₹1,026.06. GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.

Key valuation signals for NSE:ALIVUS:

  • Beginning Cash Position: ₹0 Mil
  • GF Value™: ₹1,026.06 vs. price of ₹1,329.80 (29.6% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alivus Life Sciences Business Description

Other Exchanges 543322:India
Address 470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
80GF Score

Get the complete analysis for NSE:ALIVUS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,329.80
Price
₹1,026.06
GF Value